Earnings ·
Aprea Therapeutics reported financial results for the second quarter ended June 30, 2026, revealing a net loss of $3.6…
APREAprea Therapeutics, Inc.
Aprea Therapeutics reported financial results for the second quarter ended June 30, 2026, revealing a net loss of $3.6 million, or $0.07 per basic share, on approximately 53.5 million weighted-average shares outstanding. The company held $41.2 million in cash and cash equivalents as of June 30, 2026, sufficient to fund operations into the first quarter of 2028. R&D expenses increased to $2.5 million from $1.9 million in the prior year period due to higher costs for the ACESOT-1051 trial. Clinically, enrollment in the Phase 1 dose escalation study for its WEE1 inhibitor APR-1051 is accelerating, with active sites expanding from three to ten and an expectation of reaching 6 to 10 patients per month by Q4 2026. Aprea Therapeutics operates as a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for biomarker-defined cancers.